Rebamipid

Rebamipid
Nama sistematis (IUPAC)
	2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
Data klinis
Nama dagang	Mucosta (JP), Rebagen (KR, CN, IN), Rebagit (RU)
AHFS/Drugs.com	International Drug Names
Kat. kehamilan	?
Status hukum	?
Rute	Oral (tablets)
Pengenal
Nomor CAS	90098-04-7
Kode ATC	A02BX14
PubChem	CID 5042
Ligan IUPHAR	871
DrugBank	DB11656
ChemSpider	4866
UNII	LR583V32ZR
KEGG	D01121
ChEMBL	CHEMBL1697771
Data kimia
Rumus	C19H15ClN2O4
Massa mol.	370.786 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26) ; Key:ALLWOAVDORUJLA-UHFFFAOYSA-N ;

Rebamipid adalah turunan asam amino dari 2-(1H)-quinolinon yang digunakan untuk perlindungan mukosa,^[1] penyembuhan tukak lambung (ulkus peptikum), dan pengobatan maag (gastritis).^[2] Obat ini bekerja dengan meningkatkan pertahanan mukosa, membersihkan radikal bebas,^[3] dan mengaktifkan gen penyandi siklooksigenase-2 secara sementara.^[4]

Rebamipid tersedia di sejumlah negara Asia termasuk Jepang (dipasarkan sebagai Mucosta), Korea Selatan, Cina,^[5] India (dipasarkan sebagai Rebagen), dan Rusia (dipasarkan sebagai Rebagit).^[6] Obat ini tidak disetujui oleh Badan Pengawasan Obat dan Makanan Amerika Serikat (US Food and Drug Administration).

Peneilitian telah menunjukkan bahwa rebamipid dapat melawan efek merusak NSAID pada mukosa saluran pencernaan,^[7] dan baru-baru ini pada usus halus, tetapi tidak untuk kerusakan lambung yang diinduksi naproksen.^[8] Obat juga telah dipelajari untuk pengobatan penyakit Behçet.^[9] Itu terbukti berhasil mengobati pouchitis dalam studi N-tunggal setelah terapi lini pertama untuk kondisi tersebut tidak berhasil.^[10] Beberapa penelitian telah menunjukkan efektivitas pada presbyacusis (gangguan pendengaran terkait usia).^[11]

Obat juga telah terbukti mengurangi tanda dan gejala mata kering (xerophtalmia) dalam uji coba terkontrol secara acak meskipun ini belum tersedia secara klinis.^[12]

Referensi[sunting | sunting sumber]

^ Arakawa, T.; Kobayashi, K.; Yoshikawa, T.; Tarnawski, A. (1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. ISSN 0163-2116. PMID 9753220.
^ Arakawa, T.; Watanabe, T.; Fukuda, T.; Yamasaki, K.; Kobayashi, K. (1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–2472. ISSN 0163-2116. PMID 7587834.
^ Takumida, Masaya; Anniko, Matti (2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. ISSN 1651-2251. PMID 18607930.
^ Tarnawski, A. S.; Chai, J.; Pai, R.; Chiou, S. K. (2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–209. ISSN 0163-2116. PMID 15104358.
^ drugs.com
^ "Russian State Register of Medicines. Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (dalam bahasa Russian). Diakses tanggal 10 June 2017.
^ Zhang, Shaoheng; Qing, Qing; Bai, Yang; Mao, Hua; Zhu, Wei; Chen, Qikui; Zhang, Yali; Chen, Ye (2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. ISSN 1573-2568. PMID 23456504.
^ Gagliano-Jucá, Thiago; Moreno, Ronilson A.; Zaminelli, Tiago; Napolitano, Mauro; Magalhães, Antônio Frederico N.; Carvalhaes, Aloísio; Trevisan, Miriam S.; Wallace, John L.; De Nucci, Gilberto (2016-06-04). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. ISSN 1471-230X. PMC 4893238 . PMID 27259970. Pemeliharaan CS1: Format PMC (link)
^ "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs in R&D. 4 (1): 19–28. 2003. doi:10.2165/00126839-200304010-00002. PMID 12568631.
^ http://www.wjgnet.com/1007-9327/12/656.pdf Error in webarchive template: Check |url= value. Empty.
^ Takumida, Masaya; Anniko, Matti (2005). "Radical scavengers: a remedy for presbyacusis. A pilot study". Acta Oto-Laryngologica. 125 (12): 1290–1295. doi:10.1080/00016480510037032. ISSN 0001-6489. PMID 16303676.
^ Kinoshita, S.; K. Oshiden; S. Awamura; H. Suzuki; N. Nakamichi (2013). "A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye". Ophthalmology. 120 (6): 1158–65. doi:10.1016/j.ophtha.2012.12.022. PMID 23490326.

[1] Arakawa, T.; Kobayashi, K.; Yoshikawa, T.; Tarnawski, A. (1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. ISSN 0163-2116. PMID 9753220.

[2] Arakawa, T.; Watanabe, T.; Fukuda, T.; Yamasaki, K.; Kobayashi, K. (1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–2472. ISSN 0163-2116. PMID 7587834.

[3] Takumida, Masaya; Anniko, Matti (2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. ISSN 1651-2251. PMID 18607930.

[4] Tarnawski, A. S.; Chai, J.; Pai, R.; Chiou, S. K. (2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–209. ISSN 0163-2116. PMID 15104358.

[5] rugs.com

[6] "Russian State Register of Medicines. Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (dalam bahasa Russian). Diakses tanggal 10 June 2017.

[7] Zhang, Shaoheng; Qing, Qing; Bai, Yang; Mao, Hua; Zhu, Wei; Chen, Qikui; Zhang, Yali; Chen, Ye (2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. ISSN 1573-2568. PMID 23456504.

[8] Gagliano-Jucá, Thiago; Moreno, Ronilson A.; Zaminelli, Tiago; Napolitano, Mauro; Magalhães, Antônio Frederico N.; Carvalhaes, Aloísio; Trevisan, Miriam S.; Wallace, John L.; De Nucci, Gilberto (2016-06-04). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. ISSN 1471-230X. PMC 4893238 . PMID 27259970. Pemeliharaan CS1: Format PMC (link)

[9] "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs in R&D. 4 (1): 19–28. 2003. doi:10.2165/00126839-200304010-00002. PMID 12568631.

[10] ttp://www.wjgnet.com/1007-9327/12/656.pdf Error in webarchive template: Check |url= value. Empty.

[11] Takumida, Masaya; Anniko, Matti (2005). "Radical scavengers: a remedy for presbyacusis. A pilot study". Acta Oto-Laryngologica. 125 (12): 1290–1295. doi:10.1080/00016480510037032. ISSN 0001-6489. PMID 16303676.

[12] Kinoshita, S.; K. Oshiden; S. Awamura; H. Suzuki; N. Nakamichi (2013). "A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye". Ophthalmology. 120 (6): 1158–65. doi:10.1016/j.ophtha.2012.12.022. PMID 23490326.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]